Long-term progression-free survival in a patient with extensive-stage small-cell lung cancer following second-line therapy with anlotinib and palliative chemoradiotherapy: A case report.

Lung cancer is among the most common types of malignancies, with small-cell lung cancer (SCLC) being a particularly aggressive subtype. The prognosis for SCLC is typically poor once it recurs and metastasizes after first-line treatment. Although numerous studies have investigated second-line therapies for SCLC, the outcomes have been suboptimal. In this case report, we examined the effectiveness of anlotinib combined with palliative chemoradiotherapy in a patient with second-line treatment of SCLC. The patient achieved a long progression-free survival of 31 months with anlotinib combined with palliative chemoradiotherapy. Anlotinib combined with palliative chemoradiotherapy may offer significant therapeutic benefits as a second-line recurrent or metastatic SCLC.